Article

Voluntary Recall of Antihemophilic Factor (Recombinant), Helixate FS / Kogenate FS

Author(s):

BioPharm International Editors

Potency testing following nine weeks storage at room temperature found that the lots fell below the minimum potency specification.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!
Related Videos
Related Content
Ozempic, Mounjaro and Wegovy injectable pens on white background | Image Credit: © K KStock - stock.adobe.com
September 17th 2025

FDA Warnings Sent to Lilly, Novo, Hims About Misleading Drug Communications

Patrick Lavery
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
September 17th 2025

The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game

G-CON
Cancer Cells test on laboratory test tube in the analyst's hand in a plastic glove | Image Credit: ©Giovanni Cancemi -stock.adobe.com
September 17th 2025

Biosynthetic Methods in Pharmaceutical Manufacturing

Cynthia A. Challener
Mastering Antibody-Drug Conjugates
September 17th 2025

Mastering Antibody-Drug Conjugates

BIOVECTRA
Destruction of lymphoblasts. Conceptual 3D illustration of treatment of acute lymphoblastic leukemia | Image Credit: © Dr_Microbe - stock.adobe.com
September 17th 2025

Gyala Therapeutics’ CAR-T Leukemia Therapy Shows Promise, Heads for Clinical Trial

Patrick Lavery
Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com
September 17th 2025

Monte Rosa and Novartis Partner to Target Undruggable Immunology Pathways with Degraders

Feliza Mirasol
© 2025 MJH Life Sciences

All rights reserved.